Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells

Cuiying He(Hebei Medical University), Lihong Liu(Hebei Medical University)
BMC Cancer
October 27, 2022
Cited by 8


Related Papers